SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Incyte (INCY) -- Ignore unavailable to you. Want to Upgrade?


To: tuck who wrote (3132)6/8/2017 1:05:21 PM
From: scaram(o)uche  Respond to of 3202
 
I need a list of combo's that have failed. And I hate having to google a trade name, to find a specificity or mechanism of action.

I need the sort of tables that I once kept.

:-(

I am focused on combo's that don't involve direct T cell activation or even regulation (monocytes, MDSCs, all of the stuff that hasn't worked from an investment stand), unless it's through vaccination... antigen-specific. In that regard, you could goose your trade with a discussion of those outrageously provocative (ugh) provenge results? Adjunct asst. professor. But, would have looked like a phase II holy grail, ten years ago.

Discussion of those results? Looks like it's touching an electrified third rail.



To: tuck who wrote (3132)6/8/2017 1:30:55 PM
From: scaram(o)uche  Read Replies (1) | Respond to of 3202
 
Feuerstein is referring to a manuscript, maybe published ~ 3 years ago?? Said indoximod had no direct activity on IDO. You could wade through pubmed or just ask him for a link?

Many good labs have used it, since then, as an IDO inhibitor.

Miljenko seems to have info, differentiating targets. MZ?

Go bug PGS in twitter?